Abdera Therapeutics
Vancouver
About Abdera Therapeutics
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $148.3M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2023)
- Website: abderatherapeutics.com
- Phone: 604.827.1147
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Life Science, Oncology
Social Profiles
Canonical: https://fsome.com/organization/abdera-therapeutics-20356 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.